Vaxil Bio Ltd (TSE:VXL)
:VXL
Want to see TSE:VXL full AI Analyst Report?
VXL Stock Chart & Stats
C$0.13
C$0.00(0.00%)
At close: 4:00 PM EDT
C$0.13
C$0.00(0.00%)
Day’s Range― - ―
52-Week RangeC$0.13 - C$0.33
Previous CloseN/A
Volume4.43K
Average Volume (3M)1.45K
Market Cap
C$1.06M
Enterprise Value-C$53.98K
Total Cash (Recent Filing)C$671.00K
Total Debt (Recent Filing)C$0.00
Price to Earnings (P/E)0.8
Beta-0.91
Next Earnings
Jun 01, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.17
Shares Outstanding3,984,021
10 Day Avg. Volume1,125
30 Day Avg. Volume1,453
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.30
Price to Sales (P/S)0.00
P/FCF Ratio-2.42
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / Balance Sheet StrengthLow or effectively no debt and an increased equity base materially reduce financial risk and give management latitude to fund clinical programs. This structural balance-sheet strength extends runway and supports R&D spending and partnership negotiations over the next several months.
Improving Cash-burn TrendAlthough cash flow remains negative, a meaningful reduction in burn versus prior years reflects improved capital efficiency. A sustained improvement in cash burn increases operational runway, lowers immediate financing pressure, and improves chances of advancing trials or striking non-dilutive collaborations.
Focused Clinical-stage Immunotherapy PlatformA defined immunotherapy/T-cell focus addresses durable, high-demand therapeutic areas (oncology, infectious disease). A clear clinical-stage pipeline aligns with industry partnership and milestone models, increasing prospects for strategic collaborations and non‑recurring funding that can advance programs.
Bears Say
No Commercial RevenueThe absence of product revenue and persistently negative operating results reflect a pre-commercial profile that cannot self-sustain operations. This structural lack of revenue forces reliance on external capital or partners, making program continuity sensitive to financing access and timing.
Persistent Negative Cash GenerationConsistent annual negative operating and free cash flows indicate structural cash burn tied to development activities. Even with recent improvement, ongoing negative cash generation necessitates recurring financing or deals, which can dilute equity and limit strategic flexibility over the medium term.
Earnings Volatility & Earnings Quality ConcernsNet income that turns positive despite negative operating results implies dependence on non‑operating items (e.g., financing gains, one‑offs). This undermines the signal value of reported profitability, complicates forecasting, and masks whether core R&D operations are progressing sustainably.
Vaxil Bio News
VXL FAQ
What was Vaxil Bio Ltd’s price range in the past 12 months?
Vaxil Bio Ltd lowest stock price was C$0.13 and its highest was C$0.33 in the past 12 months.
What is Vaxil Bio Ltd’s market cap?
Vaxil Bio Ltd’s market cap is C$1.06M.
When is Vaxil Bio Ltd’s upcoming earnings report date?
Vaxil Bio Ltd’s upcoming earnings report date is Jun 01, 2026 which is in 13 days.
How were Vaxil Bio Ltd’s earnings last quarter?
Currently, no data Available
Is Vaxil Bio Ltd overvalued?
According to Wall Street analysts Vaxil Bio Ltd’s price is currently Overvalued.
Does Vaxil Bio Ltd pay dividends?
Vaxil Bio Ltd does not currently pay dividends.
What is Vaxil Bio Ltd’s EPS estimate?
Vaxil Bio Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Vaxil Bio Ltd have?
Vaxil Bio Ltd has 3,984,021 shares outstanding.
What happened to Vaxil Bio Ltd’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Vaxil Bio Ltd?
Currently, no hedge funds are holding shares in TSE:VXL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Vaxil Bio Ltd
Vaxil Bio Ltd., a biotechnology company, focuses on a novel drug discovery and development platform based on signal peptides for infectious diseases and cancer. The company's lead product is ImMucin that has completed a Phase I/II clinical trial for the treatment of multiple myeloma. It is also developing a tuberculosis vaccine/treatment and a coronavirus (COVID-19) vaccine. The company has a collaboration agreement with The Tel Aviv Sourasky Medical Center for the company's research program to develop a potential peptide vaccine against COVID-19; and cooperative research and development agreement with U.S. Army Medical Research Institute of Infectious Diseases for testing CorVax for its ability to prevent COVID-19 in mice. The company was founded in 2006 and is headquartered in Toronto, Canada.
Technical Analysis
Aptose Biosciences
―
Medicenna Therapeutics Corp
―
BriaCell Therapeutics
―
BioVaxys Technology
―
Defence Therapeutics
―